Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 4—April 2011


Hepatitis A Virus Vaccine Escape Variants and Potential New Serotype Emergence

Unai Pérez-Sautu1, M. Isabel Costafreda1, Joan Caylà, Cecilia Tortajada, Josep Lite, Albert Bosch, and Rosa M. PintóComments to Author 
Author affiliations: Author affiliations: University of Barcelona, Barcelona, Spain (U. Pérez-Sautu, M.I. Costafreda, A. Bosch, R.M. Pintó); Public Health Agency of Barcelona, Barcelona (J. Caylà, C. Tortajada); CatLab, Viladecavalls, Spain (J. Lite)

Main Article

Table 2

Neutralization assays of K34C8 MAb-escape variants that showed replacements at the same or very close positions as the mutated positions in the naturally-selected field variants isolated during 2005–2009*†

Mutant (position replaced) log Nt/N0 vaccine serum (HAVRIX) log Nt/N0 vaccine serum (Avaxim) log Nt/N0 convalescent-phase serum (HCS2) log Nt/N0 MAb K34C8
C6 (1170) –0.08 ± 0.14 –0.08 ± 0.14 –0.02 ± 0.04 –0.08 ± 0.14
P29 (1187) –0.70 ± 0.09 –0.30 ± 0.19 –0.70 ± 0.07 –0.37 ± 0.19
D23 (1217) –0.88 ± 0.02 –0.54 ± 0.01 –0.61 ± 0.07 –0.58 ± 0.12
HM175/43c –0.69 ± 0.09 –0.60 ± 0.05 –0.65 ± 0.05 –0.61 ± 0.10

*Assays were performed by using vaccine and convalescent-phase serum samples as well as K34C8 MAb. MAb, monoclonal antibody; HAVRIX, HAVRIX vaccine (GlaxoSmithKline, Rixenart, Belgium); Avaxim, Avaxim vaccine (Sanofi-Pasteur, Paris, France).
†Following the model of the hepatitis A virus protomer of Ming Luo (Figure 1). Three neutralization assays were performed with each antivaccine serum sample, the convalescent-phase serum sample, and the MAb K34C8. As controls, neutralization of the D23 H7C27 MAb escape variant (9) as well as that of the HM175/43c wild-type strain, was also measured. The highest dilution showing a log Nt/N0 = –0.60 (75% neutralization) of the wild-type strain was used to test the variants; Nt, the viral titer after neutralization; N0, the initial titer. Neutralization limits were the following: log Nt/N0>–0.26 (<45%) for resistant variants, –0.26>log Nt/N0>–0.60 (45%–75%) for partially resistant variants, and log Nt/N0<–0.60 (>75%) for sensitive variants (9).

Main Article

1These authors contributed equally to this article.

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO